MGNX
Macrogenics Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Macrogenics Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
SentenceThe underlying ADC technology was licensed from Byondis B.V. (Byondis).
MGNX 10-Kaccession 0001125345-26-000017
SentenceSelling, general and administrative expense also includes legal and professional fees and included costs incurred under the arrangement with our commercialization partner, Eversana Life Science Services, LLC in 2023 and 2024.
MGNX 10-Kaccession 0001125345-26-000017
SentenceIn November 2024, we paid an $8.0 million amendment fee to Eversana Life Sciences Services, LLC (Eversana), our former partner that had previously commercialized MARGENZA.
MGNX 10-Kaccession 0001125345-26-000017
SentenceWe also rely on our licensees and contract manufacturers, including, Synaffix, Sterling and Millipore Sigma, for producing components of our ADC candidates.
MGNX 10-Kaccession 0001125345-26-000017
SentenceIn addition, we currently rely on and will continue to rely on contract fill-finish service providers, primarily PCI Pharma Services (formerly known as Ajinomoto Bio-Pharma Services), Symbiosis, and Simtra BioPharma Solutions, to fulfill our fill-finish needs for our current and future product candidates.
MGNX 10-Kaccession 0001125345-26-000017
SentenceIn addition, we currently rely on and will continue to rely on contract fill-finish service providers, primarily PCI Pharma Services (formerly known as Ajinomoto Bio-Pharma Services), Symbiosis, and Simtra BioPharma Solutions, to fulfill our fill-finish needs for our current and future product candidates.
MGNX 10-Kaccession 0001125345-26-000017
SentenceWe also rely on our licensees and contract manufacturers, including, Synaffix, Sterling and Millipore Sigma, for producing components of our ADC candidates.
MGNX 10-Kaccession 0001125345-26-000017
SentenceIn addition, we currently rely on and will continue to rely on contract fill-finish service providers, primarily PCI Pharma Services (formerly known as Ajinomoto Bio-Pharma Services), Symbiosis, and Simtra BioPharma Solutions, to fulfill our fill-finish needs for our current and future product candidates.
MGNX 10-Kaccession 0001125345-26-000017
SentenceCertain of our ADC products in development incorporate technology developed by our collaboration partners, including: MGC026 and MGC028 (incorporate Hydraspace ® , GlycoConnect™ ® , and toxSYN® technology developed by our collaboration partner, Synaffix).
MGNX 10-Kaccession 0001125345-26-000017
SentenceThis cleavable linker-payload is based on exatecan, a clinically validated and potent camptothecin, and is site-specifically conjugated using the GlycoConnect® technology developed by our collaboration partner, Synaffix B.V., a Lonza company (Synaffix).
MGNX 10-Kaccession 0001125345-26-000017
SentenceAs part of the Gilead Agreement, Gilead paid us a non-refundable upfront payment of $60.0 million and we are eligible to receive up to $1.7 billion in target nomination, option fees, and development, regulatory and commercial milestones, assuming Gilead exercises the CD123 Option and Research Program Option, successfully develops and commercializes MGD024 or other CD123 products developed under the agreement, and products result from the two additional research programs .
SentenceThe decrease of $32.7 million in revenue from collaborative and other agreements for the year ended December 31, 2025 compared to the year ended December 31, 2024 was primarily due to $100.0 million recognized from milestones under the Incyte License Agreement in 2024 compared to $50.0 million recognized from milestones under the Provention (Sanofi) Asset Purchase Agreement and $25.0 million from the Gilead Agreement in 2025.
MGNX 10-Kaccession 0001125345-26-000017
SentenceIn 2018, we entered into an asset purchase agreement (Provention APA) with Provention Bio, Inc., subsequently acquired by Sanofi S.A. (Sanofi), pursuant to which they acquired our interest in teplizumab, a mAb we had been developing for the treatment of type 1 diabetes.
MGNX 10-Kaccession 0001125345-26-000017
SentenceIn June 2025, we entered into a Purchase and Sale Agreement (Royalty Purchase Agreement) with Sagard, pursuant to which we sold to Sagard our right to receive royalties on global net sales of ZYNYZ (retifanlimab-dlwr) occurring on and after July 1, 2025 under our Incyte License Agreement, dated as of October 24, 2017, as amended.
MGNX 10-Kaccession 0001125345-26-000017
SentenceIn November 2024, we sold global rights to MARGENZA to TerSera Therapeutics, LLC (TerSera) for an upfront payment of $40.0 million, and accordingly, no longer have product sales;
MGNX 10-Kaccession 0001125345-26-000017
Macrogenics has 10 disclosed suppliers and 7 disclosed customers in SEC filings.
Linked news
Macrogenics Inc
2.41
Expected move
Inputsspot 2.40exp Nov 20ATM strike 2ATM straddle 0.62IV 126%